메뉴 건너뛰기




Volumn 14, Issue 2, 2017, Pages 100-113

Genomic complexity of multiple myeloma and its clinical implications

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; GENETIC MARKER;

EID: 84983035375     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.122     Document Type: Review
Times cited : (413)

References (130)
  • 3
    • 67049162188 scopus 로고    scopus 로고
    • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study
    • Landgren, O., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412-5417 (2009
    • (2009) Blood , vol.113 , pp. 5412-5417
    • Landgren, O.1
  • 4
    • 67049114114 scopus 로고    scopus 로고
    • A monoclonal gammopathy precedes multiple myeloma in most patients
    • Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418-5422 (2009
    • (2009) Blood , vol.113 , pp. 5418-5422
    • Weiss, B.M.1    Abadie, J.2    Verma, P.3    Howard, R.S.4    Kuehl, W.M.5
  • 5
    • 79951494668 scopus 로고    scopus 로고
    • Initial genome sequencing and analysis of multiple myeloma
    • Chapman, M. A., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011
    • (2011) Nature , vol.471 , pp. 467-472
    • Chapman, M.A.1
  • 6
    • 84892409192 scopus 로고    scopus 로고
    • Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy
    • Lohr, J. G., et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014
    • (2014) Cancer Cell , vol.25 , pp. 91-101
    • Lohr, J.G.1
  • 7
    • 84892699941 scopus 로고    scopus 로고
    • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
    • Bolli, N., et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014
    • (2014) Nat. Commun , vol.5 , pp. 2997
    • Bolli, N.1
  • 8
    • 84928558756 scopus 로고    scopus 로고
    • APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
    • Walker, B. A., et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Commun. 6, 6997 (2015
    • (2015) Nature Commun , vol.6 , pp. 6997
    • Walker, B.A.1
  • 9
    • 84947116451 scopus 로고    scopus 로고
    • Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma
    • Walker, B. A., et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol, http://dx.doi.org/10.1200/JCO.2014.59.1503 (2015
    • (2015) J. Clin. Oncol
    • Walker, B.A.1
  • 10
    • 33746364172 scopus 로고    scopus 로고
    • Familial risks and temporal incidence trends of multiple myeloma
    • Altieri, A., Chen, B., Bermejo, J. L., Castro, F., & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661-1670 (2006
    • (2006) Eur. J. Cancer , vol.42 , pp. 1661-1670
    • Altieri, A.1    Chen, B.2    Bermejo, J.L.3    Castro, F.4    Hemminki, K.5
  • 11
    • 84655166569 scopus 로고    scopus 로고
    • Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk
    • Broderick, P., et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat. Genet. 44, 58-61 (2012
    • (2012) Nat. Genet , vol.44 , pp. 58-61
    • Broderick, P.1
  • 12
    • 84885022887 scopus 로고    scopus 로고
    • Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk
    • Chubb, D., et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat. Genet. 45, 1221-1225 (2013
    • (2013) Nat. Genet , vol.45 , pp. 1221-1225
    • Chubb, D.1
  • 13
    • 84899051598 scopus 로고    scopus 로고
    • Inherited genetic susceptibility to monoclonal gammopathy of unknown significance
    • quiz 2593
    • Weinhold, N., et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 123, 2513-2517; quiz 2593, http://dx.doi.org/10.1182/blood-2013-10-532283 (2014
    • (2014) Blood , vol.123 , pp. 2513-2517
    • Weinhold, N.1
  • 14
    • 84878596524 scopus 로고    scopus 로고
    • The CCND1 c.870GA polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
    • Weinhold, N., et al. The CCND1 c.870GA polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat. Genet. 45, 522-525 (2013
    • (2013) Nat. Genet , vol.45 , pp. 522-525
    • Weinhold, N.1
  • 15
    • 84954533526 scopus 로고    scopus 로고
    • Genetic factors influencing the risk of multiple myeloma bone disease
    • Johnson, D. C., et al. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, http://dx.doi.org/10.1038/leu.2015.342 (2015
    • (2015) Leukemia
    • Johnson, D.C.1
  • 16
    • 84930226491 scopus 로고    scopus 로고
    • Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
    • Swaminathan B., et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat. Commun. 6, 7213 (2015
    • (2015) Nat. Commun , vol.6 , pp. 7213
    • Swaminathan, B.1
  • 17
    • 84937850309 scopus 로고    scopus 로고
    • Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
    • Ziv, E., et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat. Commun. 6, 7539 (2015
    • (2015) Nat. Commun , vol.6 , pp. 7539
    • Ziv, E.1
  • 18
    • 84904055840 scopus 로고    scopus 로고
    • Racial disparities in the prevalence of monoclonal gammopathies: A population-based study of 12,482 persons from the National Health and Nutritional Examination Survey
    • Landgren, O., et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28, 1537-1542 (2014
    • (2014) Leukemia , vol.28 , pp. 1537-1542
    • Landgren, O.1
  • 19
    • 36148961606 scopus 로고    scopus 로고
    • Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
    • Gonzalez, D., et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112-3121 (2007
    • (2007) Blood , vol.110 , pp. 3112-3121
    • Gonzalez, D.1
  • 20
    • 22044440425 scopus 로고    scopus 로고
    • Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma
    • Bergsagel, P. L., et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296-303 (2005
    • (2005) Blood , vol.106 , pp. 296-303
    • Bergsagel, P.L.1
  • 21
    • 26944484104 scopus 로고    scopus 로고
    • Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma
    • Ross, F. M., et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19, 1634-1642 (2005
    • (2005) Leukemia , vol.19 , pp. 1634-1642
    • Ross, F.M.1
  • 22
    • 8844266049 scopus 로고    scopus 로고
    • Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
    • Kaufmann, H., et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 18, 1879-1882 (2004
    • (2004) Leukemia , vol.18 , pp. 1879-1882
    • Kaufmann, H.1
  • 23
    • 0037103287 scopus 로고    scopus 로고
    • Genomic abnormalities in monoclonal gammopathy of undetermined significance
    • Fonseca, R., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100, 1417-1424 (2002
    • (2002) Blood , vol.100 , pp. 1417-1424
    • Fonseca, R.1
  • 24
    • 0033568514 scopus 로고    scopus 로고
    • 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma
    • Avet-Loiseau, H., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone Myelome. Cancer Res. 59, 4546-4550 (1999
    • (1999) Intergroupe Francophone Myelome Cancer Res , vol.59 , pp. 4546-4550
    • Avet-Loiseau, H.1
  • 25
    • 0029978550 scopus 로고    scopus 로고
    • Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
    • Chesi, M., et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674-681 (1996
    • (1996) Blood , vol.88 , pp. 674-681
    • Chesi, M.1
  • 26
    • 0030030584 scopus 로고    scopus 로고
    • Regulation of the catalytic subunit (p34PSK J3/cdk4) for the major D type cyclin in mature B lymphocytes
    • Tanguay, D. A., & Chiles, T. C. Regulation of the catalytic subunit (p34PSK J3/cdk4) for the major D type cyclin in mature B lymphocytes. J. Immunol. 156, 539-548 (1996
    • (1996) J. Immunol , vol.156 , pp. 539-548
    • Tanguay, D.A.1    Chiles, T.C.2
  • 27
    • 10144241685 scopus 로고    scopus 로고
    • Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes
    • Solvason, N., et al. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes. J. Exp. Med. 184, 407-417 (1996
    • (1996) J. Exp. Med , vol.184 , pp. 407-417
    • Solvason, N.1
  • 28
    • 84879399749 scopus 로고    scopus 로고
    • Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
    • Walker, B. A., et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121, 3413-3419 (2013
    • (2013) Blood , vol.121 , pp. 3413-3419
    • Walker, B.A.1
  • 29
    • 33745779502 scopus 로고    scopus 로고
    • The molecular classification of multiple myeloma
    • Zhan, F., et al. The molecular classification of multiple myeloma. Blood 108, 2020-2028 (2006
    • (2006) Blood , vol.108 , pp. 2020-2028
    • Zhan, F.1
  • 30
    • 0037441747 scopus 로고    scopus 로고
    • In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
    • Keats, J. J., et al. In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101, 1520-1529 (2003
    • (2003) Blood , vol.101 , pp. 1520-1529
    • Keats, J.J.1
  • 31
    • 0038142356 scopus 로고    scopus 로고
    • Clinical and biologic implications of recurrent genomic aberrations in myeloma
    • Fonseca, R., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101, 4569-4575 (2003
    • (2003) Blood , vol.101 , pp. 4569-4575
    • Fonseca, R.1
  • 32
    • 1842557964 scopus 로고    scopus 로고
    • The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
    • Chang, H., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br. J. Haematol. 125, 64-68 (2004
    • (2004) Br. J. Haematol , vol.125 , pp. 64-68
    • Chang, H.1
  • 33
    • 33847378314 scopus 로고    scopus 로고
    • Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome
    • Avet-Loiseau, H., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109, 3489-3495 (2007
    • (2007) Blood , vol.109 , pp. 3489-3495
    • Avet-Loiseau, H.1
  • 34
    • 0032212243 scopus 로고    scopus 로고
    • The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
    • Chesi, M., et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92, 3025-3034 (1998
    • (1998) Blood , vol.92 , pp. 3025-3034
    • Chesi, M.1
  • 35
    • 0037443417 scopus 로고    scopus 로고
    • A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
    • Santra M., Zhan, F., Tian, E., Barlogie, B., & Shaughnessy, J. Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101, 2374-2376 (2003
    • (2003) Blood , vol.101 , pp. 2374-2376
    • Santra, M.1    Zhan, F.2    Tian, E.3    Barlogie, B.4    Shaughnessy, J.5
  • 36
    • 20844463416 scopus 로고    scopus 로고
    • Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
    • Keats, J. J., et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 105, 4060-4069 (2005
    • (2005) Blood , vol.105 , pp. 4060-4069
    • Keats, J.J.1
  • 37
    • 78650978001 scopus 로고    scopus 로고
    • The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
    • Martinez-Garcia, E., et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211-220 (2011
    • (2011) Blood , vol.117 , pp. 211-220
    • Martinez-Garcia, E.1
  • 38
    • 79551665780 scopus 로고    scopus 로고
    • MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
    • Pei, H., et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124-128 (2011
    • (2011) Nature , vol.470 , pp. 124-128
    • Pei, H.1
  • 39
    • 0032841519 scopus 로고    scopus 로고
    • Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
    • Cappellen, D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet. 23, 18-20 (1999
    • (1999) Nature Genet , vol.23 , pp. 18-20
    • Cappellen, D.1
  • 40
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel, J. F., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008
    • (2008) N. Engl. J. Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1
  • 41
    • 78049501226 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p
    • Avet-Loiseau, H., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630-4634 (2010
    • (2010) J. Clin. Oncol , vol.28 , pp. 4630-4634
    • Avet-Loiseau, H.1
  • 42
    • 0034935624 scopus 로고    scopus 로고
    • Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations
    • Hanamura, I., et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn. J. Cancer Res. 92, 638-644 (2001
    • (2001) Jpn. J. Cancer Res , vol.92 , pp. 638-644
    • Hanamura, I.1
  • 43
    • 1442285889 scopus 로고    scopus 로고
    • Overexpression of c maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
    • Hurt, E. M., et al. Overexpression of c maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5, 191-199 (2004
    • (2004) Cancer Cell , vol.5 , pp. 191-199
    • Hurt, E.M.1
  • 44
    • 79951504474 scopus 로고    scopus 로고
    • Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor?
    • Avet-Loiseau, H., et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 117, 2009-2011 (2011
    • (2011) Blood , vol.117 , pp. 2009-2011
    • Avet-Loiseau, H.1
  • 46
    • 0035412392 scopus 로고    scopus 로고
    • Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
    • Shaughnessy Jr. J. et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98, 217-223 (2001
    • (2001) Blood , vol.98 , pp. 217-223
    • Shaughnessy, J.1
  • 47
    • 84876571691 scopus 로고    scopus 로고
    • Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-Adapted therapy (msmart) consensus guidelines 2013
    • Mikhael, J. R., et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360-376 (2013
    • (2013) Mayo Clin. Proc , vol.88 , pp. 360-376
    • Mikhael, J.R.1
  • 48
    • 77954516403 scopus 로고    scopus 로고
    • The t(14;20) is a poor prognostic factor in myeloma but is associated with long-Term stable disease in monoclonal gammopathies of undetermined significance
    • Ross, F. M., et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-Term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95, 1221-1225 (2010
    • (2010) Haematologica , vol.95 , pp. 1221-1225
    • Ross, F.M.1
  • 49
    • 0035892119 scopus 로고    scopus 로고
    • Rearrangements of the c myc oncogene are present in 15% of primary human multiple myeloma tumors
    • Avet-Loiseau, H., et al. Rearrangements of the c myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98, 3082-3086 (2001
    • (2001) Blood , vol.98 , pp. 3082-3086
    • Avet-Loiseau, H.1
  • 50
    • 84959313198 scopus 로고    scopus 로고
    • Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma
    • Weinhold, N., et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica http://dx.doi.org/10.3324/haematol.2015.136929 2015
    • (2015) Haematologica
    • Weinhold, N.1
  • 51
    • 84955592205 scopus 로고    scopus 로고
    • Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair
    • Haradhvala, N. J., et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell 164, 538-549 (2016
    • (2016) Cell , vol.164 , pp. 538-549
    • Haradhvala, N.J.1
  • 52
    • 84905705842 scopus 로고    scopus 로고
    • Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
    • Affer, M., et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28, 1725-1735 (2014
    • (2014) Leukemia , vol.28 , pp. 1725-1735
    • Affer, M.1
  • 53
    • 84901846972 scopus 로고    scopus 로고
    • Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
    • Walker, B. A., et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 4, e191 (2014
    • (2014) Blood Cancer J. , vol.4 , pp. e191
    • Walker, B.A.1
  • 54
    • 33645769276 scopus 로고    scopus 로고
    • High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
    • Carrasco, D. R., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313-325 (2006
    • (2006) Cancer Cell , vol.9 , pp. 313-325
    • Carrasco, D.R.1
  • 55
    • 77957949804 scopus 로고    scopus 로고
    • A compendium of myeloma-Associated chromosomal copy number abnormalities and their prognostic value
    • Walker, B. A., et al. A compendium of myeloma-Associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56-65 (2010
    • (2010) Blood , vol.116 , pp. e56-65
    • Walker, B.A.1
  • 56
    • 33748190743 scopus 로고    scopus 로고
    • Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
    • Walker, B. A., et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108, 1733-1743 (2006
    • (2006) Blood , vol.108 , pp. 1733-1743
    • Walker, B.A.1
  • 57
    • 34547562418 scopus 로고    scopus 로고
    • Frequent engagement of the classical and alternative NF kappaB pathways by diverse genetic abnormalities in multiple myeloma
    • Annunziata, C. M., et al. Frequent engagement of the classical and alternative NF kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007
    • (2007) Cancer Cell , vol.12 , pp. 115-130
    • Annunziata, C.M.1
  • 58
    • 34547660308 scopus 로고    scopus 로고
    • Promiscuous mutations activate the noncanonical NF kappaB pathway in multiple myeloma
    • Keats, J. J., et al. Promiscuous mutations activate the noncanonical NF kappaB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007
    • (2007) Cancer Cell , vol.12 , pp. 131-144
    • Keats, J.J.1
  • 59
    • 0031861960 scopus 로고    scopus 로고
    • Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases
    • Smadja, N. V., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12, 960-969 (1998
    • (1998) Leukemia , vol.12 , pp. 960-969
    • Smadja, N.V.1
  • 60
    • 20244363331 scopus 로고    scopus 로고
    • Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma
    • Debes-Marun, C. S., et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17, 427-436 (2003
    • (2003) Leukemia , vol.17 , pp. 427-436
    • Debes-Marun, C.S.1
  • 61
    • 24744434736 scopus 로고    scopus 로고
    • A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
    • Chng, W. J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106, 2156-2161 (2005
    • (2005) Blood , vol.106 , pp. 2156-2161
    • Chng, W.J.1
  • 62
    • 0026748638 scopus 로고
    • Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia
    • Onodera, N., McCabe, N. R., & Rubin, C. M. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 80, 203-208 (1992
    • (1992) Blood , vol.80 , pp. 203-208
    • Onodera, N.1    McCabe, N.R.2    Rubin, C.M.3
  • 63
    • 0141481984 scopus 로고    scopus 로고
    • The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
    • Fonseca, R., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102, 2562-2567 (2003
    • (2003) Blood , vol.102 , pp. 2562-2567
    • Fonseca, R.1
  • 64
    • 84921759744 scopus 로고    scopus 로고
    • Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
    • Pawlyn, C., et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 125, 831-840 (2015
    • (2015) Blood , vol.125 , pp. 831-840
    • Pawlyn, C.1
  • 65
    • 34248201056 scopus 로고    scopus 로고
    • Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    • Chng, W. J., et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 67, 2982-2989 (2007
    • (2007) Cancer Res , vol.67 , pp. 2982-2989
    • Chng, W.J.1
  • 66
    • 0035496928 scopus 로고    scopus 로고
    • Hypodiploidy is a major prognostic factor in multiple myeloma
    • Smadja, N. V., et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98, 2229-2238 (2001
    • (2001) Blood , vol.98 , pp. 2229-2238
    • Smadja, N.V.1
  • 67
    • 84951335681 scopus 로고    scopus 로고
    • Understanding the role of hyperdiploidy in myeloma prognosis: Which trisomies really matter?
    • Chretien, M. L., et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood 126, 2713-2719 (2015
    • (2015) Blood , vol.126 , pp. 2713-2719
    • Chretien, M.L.1
  • 68
    • 29244455863 scopus 로고    scopus 로고
    • Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma
    • Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10 (Suppl. 1), 117-126, http://dx.doi.org/10.1080/10245330512331390140 (2005
    • (2005) Hematology , vol.10 , pp. 117-126
    • Shaughnessy, J.1
  • 69
    • 0032030675 scopus 로고    scopus 로고
    • Jumping translocations of chromosome 1q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin
    • Sawyer, J. R., Tricot, G., Mattox, S., Jagannath, S., & Barlogie, B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91, 1732-1741 (1998
    • (1998) Blood , vol.91 , pp. 1732-1741
    • Sawyer, J.R.1    Tricot, G.2    Mattox, S.3    Jagannath, S.4    Barlogie, B.5
  • 70
    • 84899046793 scopus 로고    scopus 로고
    • Jumping translocations of 1q12 in multiple myeloma: A novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
    • Sawyer, J. R., et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood 123, 2504-2512 (2014
    • (2014) Blood , vol.123 , pp. 2504-2512
    • Sawyer, J.R.1
  • 71
    • 77954590686 scopus 로고    scopus 로고
    • 1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma
    • Fournier, A., et al. 1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma. EMBO Mol. Med. 2, 159-171 (2010
    • (2010) EMBO Mol. Med , vol.2 , pp. 159-171
    • Fournier, A.1
  • 72
    • 84862833471 scopus 로고    scopus 로고
    • Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
    • Shi, L., et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1, 22-33 (2010
    • (2010) Oncotarget , vol.1 , pp. 22-33
    • Shi, L.1
  • 73
    • 33748196399 scopus 로고    scopus 로고
    • Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
    • Hanamura, I., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724-1732 (2006
    • (2006) Blood , vol.108 , pp. 1724-1732
    • Hanamura, I.1
  • 74
    • 84055212016 scopus 로고    scopus 로고
    • Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
    • Boyd K. D., et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res.17, 7776-7784 2011
    • (2011) Clin. Cancer Res , vol.17 , pp. 7776-7784
    • Boyd, K.D.1
  • 75
    • 78649286046 scopus 로고    scopus 로고
    • Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
    • Chang, H., et al. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk. Lymphoma 51, 2084-2091 (2010
    • (2010) Leuk. Lymphoma , vol.51 , pp. 2084-2091
    • Chang, H.1
  • 76
    • 74549190701 scopus 로고    scopus 로고
    • Prognostic significance of copy-number alterations in multiple myeloma
    • Avet-Loiseau, H., et al. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 27, 4585-4590 (2009
    • (2009) J. Clin. Oncol , vol.27 , pp. 4585-4590
    • Avet-Loiseau, H.1
  • 77
    • 75149176289 scopus 로고    scopus 로고
    • 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma
    • Chang, H., et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 45, 117-121 (2010
    • (2010) Bone Marrow Transplant , vol.45 , pp. 117-121
    • Chang, H.1
  • 78
    • 0034988904 scopus 로고    scopus 로고
    • Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy
    • Fonseca, R., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15, 981-986 (2001
    • (2001) Leukemia , vol.15 , pp. 981-986
    • Fonseca, R.1
  • 79
    • 0032857034 scopus 로고    scopus 로고
    • Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
    • Avet-Loiseau, H., et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone Myelome. Blood 94, 2583-2589 (1999
    • (1999) Intergroupe Francophone Myelome. Blood , vol.94 , pp. 2583-2589
    • Avet-Loiseau, H.1
  • 80
    • 33747611919 scopus 로고    scopus 로고
    • Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
    • Chiecchio, L., et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20, 1610-1617 (2006
    • (2006) Leukemia , vol.20 , pp. 1610-1617
    • Chiecchio, L.1
  • 81
    • 0034490134 scopus 로고    scopus 로고
    • Intergroupe Francophone du MyéLome Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13
    • Avet-Louseau, H. Daviet, A., Sauner, S., Bataille, R., & Intergroupe Francophone du Myélome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol. 111, 1116-1117 (2000
    • (2000) Br. J. Haematol , vol.111 , pp. 1116-1117
    • Avet-Louseau, H.1    Daviet, A.2    Sauner, S.3    Bataille, R.4
  • 82
    • 74049162897 scopus 로고    scopus 로고
    • International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
    • Fonseca, R., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210-2221 (2009
    • (2009) Leukemia , vol.23 , pp. 2210-2221
    • Fonseca, R.1
  • 83
    • 0028880424 scopus 로고
    • Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
    • Tricot, G., et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86, 4250-4256 (1995
    • (1995) Blood , vol.86 , pp. 4250-4256
    • Tricot, G.1
  • 84
    • 43749090639 scopus 로고    scopus 로고
    • Genetic aberrations and survival in plasma cell leukemia
    • Tiedemann, R. E., et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 22, 1044-1052 (2008
    • (2008) Leukemia , vol.22 , pp. 1044-1052
    • Tiedemann, R.E.1
  • 85
    • 78149246124 scopus 로고    scopus 로고
    • Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
    • Lode, L., et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95, 1973-1976 (2010
    • (2010) Haematologica , vol.95 , pp. 1973-1976
    • Lode, L.1
  • 86
    • 0032147210 scopus 로고    scopus 로고
    • Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy
    • Drach, J., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92, 802-809 (1998
    • (1998) Blood , vol.92 , pp. 802-809
    • Drach, J.1
  • 87
    • 84951020021 scopus 로고    scopus 로고
    • Revised international staging system for multiple myeloma: A report from international myeloma working group
    • Palumbo, A., et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J. Clin. Oncol. 33, 2863-2869 (2015
    • (2015) J. Clin. Oncol , vol.33 , pp. 2863-2869
    • Palumbo, A.1
  • 88
    • 38049100456 scopus 로고    scopus 로고
    • Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
    • Beroukhim, R., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007
    • (2007) Proc. Natl Acad. Sci. USA , vol.104 , pp. 20007-20012
    • Beroukhim, R.1
  • 89
    • 77249119762 scopus 로고    scopus 로고
    • The landscape of somatic copy-number alteration across human cancers
    • Beroukhim, R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010
    • (2010) Nature , vol.463 , pp. 899-905
    • Beroukhim, R.1
  • 90
    • 84885008220 scopus 로고    scopus 로고
    • Pan-cancer patterns of somatic copy number alteration
    • Zack, T. I., et al. Pan-cancer patterns of somatic copy number alteration. Nature Genet. 45, 1134-1140 (2013
    • (2013) Nature Genet , vol.45 , pp. 1134-1140
    • Zack, T.I.1
  • 91
    • 84880507665 scopus 로고    scopus 로고
    • Mutational heterogeneity in cancer and the search for new cancer-Associated genes
    • Lawrence, M. S., et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
    • (2013) Nature , vol.499 , pp. 214-218
    • Lawrence, M.S.1
  • 92
    • 84892833777 scopus 로고    scopus 로고
    • Discovery and saturation analysis of cancer genes across 21 tumour types
    • Lawrence, M. S., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
    • (2014) Nature , vol.505 , pp. 495-501
    • Lawrence, M.S.1
  • 93
    • 84882837534 scopus 로고    scopus 로고
    • Signatures of mutational processes in human cancer
    • Alexandrov, L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
    • (2013) Nature , vol.500 , pp. 415-421
    • Alexandrov, L.B.1
  • 94
    • 84861541343 scopus 로고    scopus 로고
    • Mutational processes molding the genomes of 21 breast cancers
    • Nik-Zainal, S., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012
    • (2012) Cell , vol.149 , pp. 979-993
    • Nik-Zainal, S.1
  • 95
    • 84925664415 scopus 로고    scopus 로고
    • ATM and ATR as therapeutic targets in cancer
    • Weber, A. M., & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 149, 124-138 (2015
    • (2015) Pharmacol. Ther , vol.149 , pp. 124-138
    • Weber, A.M.1    Ryan, A.J.2
  • 96
    • 33846068920 scopus 로고    scopus 로고
    • A single subunit, Dis3, is essentially responsible for yeast exosome core activity
    • Dziembowski, A., Lorentzen, E., Conti, E., & Seraphin, B. A single subunit, Dis3, is essentially responsible for yeast exosome core activity. Nat. Struct. Mol. Biol. 14, 15-22 (2007
    • (2007) Nat. Struct. Mol. Biol , vol.14 , pp. 15-22
    • Dziembowski, A.1    Lorentzen, E.2    Conti, E.3    Seraphin, B.4
  • 97
    • 52949089292 scopus 로고    scopus 로고
    • The exosome: A multipurpose RNA-decay machine
    • Schmid, M., & Jensen, T. H. The exosome: a multipurpose RNA-decay machine. Trends Biochem. Sci. 33, 501-510 (2008
    • (2008) Trends Biochem. Sci , vol.33 , pp. 501-510
    • Schmid, M.1    Jensen, T.H.2
  • 98
    • 84925152740 scopus 로고    scopus 로고
    • The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma
    • Weissbach, S., et al. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br. J. Haematol. 169, 57-70 (2015
    • (2015) Br. J. Haematol , vol.169 , pp. 57-70
    • Weissbach, S.1
  • 99
    • 33646569453 scopus 로고    scopus 로고
    • Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B cell lymphomas
    • Tam, W., et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B cell lymphomas. Blood 107, 4090-4100 (2006
    • (2006) Blood , vol.107 , pp. 4090-4100
    • Tam, W.1
  • 100
    • 33344454909 scopus 로고    scopus 로고
    • Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma
    • Pasqualucci, L., et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311-317 (2006
    • (2006) J. Exp. Med , vol.203 , pp. 311-317
    • Pasqualucci, L.1
  • 101
    • 84891861044 scopus 로고    scopus 로고
    • Clonal evolution in hematological malignancies and therapeutic implications
    • Landau, D. A., Carter, S. L., Getz, G., & Wu, C. J. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28, 34-43 (2014
    • (2014) Leukemia , vol.28 , pp. 34-43
    • Landau, D.A.1    Carter, S.L.2    Getz, G.3    Wu, C.J.4
  • 102
    • 78751644099 scopus 로고    scopus 로고
    • Genetic variegation of clonal architecture and propagating cells in leukaemia
    • Anderson, K., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011
    • (2011) Nature , vol.469 , pp. 356-361
    • Anderson, K.1
  • 103
    • 84864570434 scopus 로고    scopus 로고
    • Darwinian evolution and tiding clones in multiple myeloma
    • Bahlis, N. J. Darwinian evolution and tiding clones in multiple myeloma. Blood 120, 927-928 (2012
    • (2012) Blood , vol.120 , pp. 927-928
    • Bahlis, N.J.1
  • 104
    • 84860782006 scopus 로고    scopus 로고
    • Absolute quantification of somatic DNA alterations in human cancer
    • Carter, S. L., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012
    • (2012) Nat. Biotechnol , vol.30 , pp. 413-421
    • Carter, S.L.1
  • 105
    • 84874102335 scopus 로고    scopus 로고
    • Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
    • Landau, D. A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013
    • (2013) Cell , vol.152 , pp. 714-726
    • Landau, D.A.1
  • 106
    • 84905690692 scopus 로고    scopus 로고
    • Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
    • Melchor, L., et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 28, 1705-1715 (2014
    • (2014) Leukemia , vol.28 , pp. 1705-1715
    • Melchor, L.1
  • 107
    • 0141993685 scopus 로고    scopus 로고
    • Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases
    • Smadja, N. V., et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38, 234-239 (2003
    • (2003) Genes Chromosomes Cancer , vol.38 , pp. 234-239
    • Smadja, N.V.1
  • 108
    • 84893810104 scopus 로고    scopus 로고
    • Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
    • Walker, B. A., et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 384-390 (2014
    • (2014) Leukemia , vol.28 , pp. 384-390
    • Walker, B.A.1
  • 109
    • 20644460600 scopus 로고    scopus 로고
    • International staging system for multiple myeloma
    • Greipp, P. R., et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412-3420 (2005
    • (2005) J. Clin. Oncol , vol.23 , pp. 3412-3420
    • Greipp, P.R.1
  • 110
    • 84881490568 scopus 로고    scopus 로고
    • Targeting the BRAF V600E mutation in multiple myeloma
    • Andrulis, M., et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 3, 862-869 (2013
    • (2013) Cancer Discov , vol.3 , pp. 862-869
    • Andrulis, M.1
  • 111
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-Type BRAF
    • Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-Type BRAF. Nature 464, 427-430 (2010
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 112
    • 84863919927 scopus 로고    scopus 로고
    • Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    • Lonial, S., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953-1959 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 1953-1959
    • Lonial, S.1
  • 113
    • 84862672400 scopus 로고    scopus 로고
    • Phase i trial of anti CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    • Jakubowiak, A. J., et al. Phase I trial of anti CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J. Clin. Oncol. 30, 1960-1965 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 1960-1965
    • Jakubowiak, A.J.1
  • 114
    • 84942436321 scopus 로고    scopus 로고
    • Targeting cd38 with daratumumab monotherapy in multiple myeloma
    • Lokhorst, H. M., et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N. Engl. J. Med. 373, 1207-1219 (2015
    • (2015) N. Engl. J. Med , vol.373 , pp. 1207-1219
    • Lokhorst, H.M.1
  • 115
    • 84953325096 scopus 로고    scopus 로고
    • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
    • Lonial, S., et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387, 1551-1560 (2016
    • (2016) Lancet , vol.387 , pp. 1551-1560
    • Lonial, S.1
  • 116
    • 84877087137 scopus 로고    scopus 로고
    • B Cell maturation antigen is a promising target for adoptive T cell therapy of multiple myeloma
    • Carpenter R. O., et al. B Cell maturation antigen is a promising target for adoptive T cell therapy of multiple myeloma. Clin. Cancer Res.19, 2048-2060 2013
    • (2013) Clin. Cancer Res , vol.19 , pp. 2048-2060
    • Carpenter, R.O.1
  • 117
    • 84978399754 scopus 로고    scopus 로고
    • Clinical responses with T lymphocytes targeting malignancy-Associated kappa light chains
    • Ramos, C. A., et al. Clinical responses with T lymphocytes targeting malignancy-Associated kappa light chains. J. Clin. Invest. http://dx.doi.org/10.1172/JCI86000 (2016
    • (2016) J. Clin. Invest
    • Ramos, C.A.1
  • 118
    • 84979240618 scopus 로고    scopus 로고
    • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
    • Lesokhin A. M., et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.65.9789 (2016
    • (2016) J. Clin. Oncol
    • Lesokhin, A.M.1
  • 119
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti PD L1 antibody MPDL3280A in cancer patients
    • Herbst, R. S., et al. Predictive correlates of response to the anti PD L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1
  • 120
    • 84928770388 scopus 로고    scopus 로고
    • Neoantigens in cancer immunotherapy
    • Schumacher, T. N., & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015
    • (2015) Science , vol.348 , pp. 69-74
    • Schumacher, T.N.1    Schreiber, R.D.2
  • 121
    • 84856013431 scopus 로고    scopus 로고
    • Clonal evolution in cancer
    • Greaves, M., & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012
    • (2012) Nature , vol.481 , pp. 306-313
    • Greaves, M.1    Maley, C.C.2
  • 122
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 123
    • 84871720411 scopus 로고    scopus 로고
    • Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study
    • Janne, P. A., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38-47 (2013
    • (2013) Lancet Oncol , vol.14 , pp. 38-47
    • Janne, P.A.1
  • 124
    • 43749103335 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY 142886) in patients with advanced cancers
    • Adjei, A. A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY 142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008
    • (2008) J. Clin. Oncol , vol.26 , pp. 2139-2146
    • Adjei, A.A.1
  • 125
    • 84899512149 scopus 로고    scopus 로고
    • Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-And NRAS-mutant malignancies
    • Abdel-Wahab, O., et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-And NRAS-mutant malignancies. Cancer Discov. 4, 538-545 (2014
    • (2014) Cancer Discov , vol.4 , pp. 538-545
    • Abdel-Wahab, O.1
  • 126
    • 78650847770 scopus 로고    scopus 로고
    • Selective inhibition of BET bromodomains
    • Filippakopoulos, P., et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010
    • (2010) Nature , vol.468 , pp. 1067-1073
    • Filippakopoulos, P.1
  • 127
    • 84871491773 scopus 로고    scopus 로고
    • FGFR genetic alterations predict for sensitivity to NVP BGJ398, a selective pan-FGFR inhibitor
    • Guagnano, V., et al. FGFR genetic alterations predict for sensitivity to NVP BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118-1133 (2012
    • (2012) Cancer Discov , vol.2 , pp. 1118-1133
    • Guagnano, V.1
  • 128
    • 84860120185 scopus 로고    scopus 로고
    • AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
    • Gavine, P. R., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045-2056 (2012
    • (2012) Cancer Res , vol.72 , pp. 2045-2056
    • Gavine, P.R.1
  • 129
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty, K. T., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010
    • (2010) N. Engl. J. Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1
  • 130
    • 33747872306 scopus 로고    scopus 로고
    • A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
    • Baughn, L. B., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66, 7661-7667 (2006
    • (2006) Cancer Res , vol.66 , pp. 7661-7667
    • Baughn, L.B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.